Trial · NCT00129766
Results by group71
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 71
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of RSV Hospitalization (Includes Deaths by RSV) | Palivizumab | 62 | Participants | ||
| Incidence of RSV Hospitalization (Includes Deaths by RSV) | Motavizumab | 46 | Participants | ||
| Number of Participants Reporting Any Adverse Events (AEs) | Palivizumab | 2837 | participants | ||
| Number of Participants Reporting Any Adverse Events (AEs) | Motavizumab | 2839 | participants | ||
| Number of Participants Reporting Any Related AEs | Palivizumab | 258 | participants | ||
| Number of Participants Reporting Any Related AEs | Motavizumab | 298 | participants | ||
| Number of Participants Reporting Any Serious Adverse Events (SAEs) | Palivizumab | 506 | participants | ||
| Number of Participants Reporting Any Serious Adverse Events (SAEs) | Motavizumab | 485 | participants | ||
| Number of Participants Reporting Any Related SAEs | Palivizumab | 8 | participants | ||
| Number of Participants Reporting Any Related SAEs | Motavizumab | 9 | participants | ||
| Number of Participants Reporting AEs by Highest Severity Grade | Palivizumab | Level 1 | 1478 | participants | |
| Number of Participants Reporting AEs by Highest Severity Grade | Motavizumab | Level 1 | 1538 | participants | |
| Number of Participants Reporting AEs by Highest Severity Grade | Palivizumab | Level 2 | 1006 | participants | |
| Number of Participants Reporting AEs by Highest Severity Grade | Motavizumab | Level 2 | 976 | participants | |
| Number of Participants Reporting AEs by Highest Severity Grade | Palivizumab | Level 3 | 292 | participants | |
| Number of Participants Reporting AEs by Highest Severity Grade | Motavizumab | Level 3 | 271 | participants | |
| Number of Participants Reporting AEs by Highest Severity Grade | Palivizumab | Level 4 | 61 | participants | |
| Number of Participants Reporting AEs by Highest Severity Grade | Motavizumab | Level 4 | 54 | participants | |
| Number of Participants Who Discontinued Study Drug Due to AEs | Palivizumab | 10 | participants | ||
| Number of Participants Who Discontinued Study Drug Due to AEs | Motavizumab | 13 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00129766/results